ArticleJournal of hepatocellular carcinoma2026
Intratumoral Fibrosis is a Potential Biomarker in Patients with Hepatocellular Carcinoma Undergoing Liver Resection.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intratumoral fibrosis (ITF) has been demonstrated to influence the prognosis of various fibrotic solid tumors. Thus, this study aimed to validate its role as a potential prognostic biomarker in patients with hepatocellular carcinoma (HCC) undergoing liver resection. Methods: This investigation enrolled 367 adult patients diagnosed with HCC who underwent liver resection. The patients were classified into high- (score ≥ 2) and low-ITF (score < 2) groups based on a semiquantitative Sirius red staining scale (0-3). IHC staining for CD34 was performed on resected samples to determine microvascular density (MVD) and to investigate the association between ITF and tumor vascularization. Cox proportional hazards regression with backward stepwise selection was employed to identify independent predictors for early HCC recurrence. Moreover, to mitigate the impact of confounding factors, propensity score matching (PSM) was conducted between patients in the high- and low-ITF groups. Lastly, the Kaplan-Meier method was utilized to assess and compare the disease-free survival (DFS) and overall survival (OS) between the two cohorts. Results: The study categorized patients into high-ITF and low-ITF groups. Backward stepwise Cox regression analysis revealed that liver cirrhosis (P<0.001), serum monocyte count (P<0.001), AFP >200 ng/mL (P<0.001), substantial intratumoral necrosis (P<0.001), presence of intratumoral artery (P<0.001), nodule-in-nodule architecture (P<0.001), and high-ITF (P<0.001) were significantly associated with early HCC recurrence. Furthermore, the results suggested that DFS and OS were significantly shorter in the high-ITF group compared to the low-ITF group, both before and after PSM (P<0.05). Finally, compared to low-ITF HCCs, high-ITF HCCs were more frequently associated with high MVD counts (54.0, IQR: 43.0-67.5 vs. 45.0, IQR: 30.0-58.0, P<0.001). Conclusion: ITF holds promise as a prognostic biomarker for early recurrence and prognosis in patients with HCC who underwent liver resection, with practical applicability for developing personalized treatment strategies for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.